Optimización del uso de Trastuzumab 440mg en el Hospital de Alta Complejidad “Virgen de la Puerta”, febrero - diciembre 2017

• Autor: Sánchez Valdez, Heisler James
• Formato: tesis de grado
• Fecha de Publicación: 2020
• Institución: Universidad Nacional de Trujillo
• Repositorio: UNITRU-Tesis
• Lenguaje: español
• OAI Identifier: oai:dspace.unitru.edu.pe:20.500.14414/17694
• Enlace del recurso: https://hdl.handle.net/20.500.14414/17694
• Nivel de acceso: acceso abierto
• Materia: Cáncer de mama; Consumo; Devolución; HER2+; Trastuzumab; Unidad de Mezclas Oncológicas; Optimización

Cancer is the process of uncontrolled growth and spread of cells in the body, and it can be located anywhere in the body. Every year the cases increase. Among the most frequent types of cancer in women, we have the cervix and breast. For the treatment of breast cancer, the stage of the disease must be taken into account. Trastuzumab is one of the drugs of choice for targeted therapy treatment in breast cancer, it tests positive when cancer cells have high levels of a protein called human epidermal growth factor receptor 2 (HER2). Trastuzumab binds to the HER2 protein and blocks the receptor. This prevents cells from dividing and growing abnormally. The report evaluated the optimization of the use of Trastuzumab 440mg in the Hospital de Alta Complexidad "Virgen de la Puerta" (HACVP), in the months of February-December 2017. Data on the consumption and return of Trastuzumab 440mg were taken by the Mixtures Unit Oncology (UMO), to Supervised Drug Pharmacy (MACS); The information was compiled from the database of the Hospital Management System (SGH), of the HACVP Pharmacy Service. The results obtained during the investigation period show that the UMO generated a total remainder of 146 units of Trastuzumab 440mg that represent an economic value of 759 251.10 soles; being the month of August where the greatest savings were generated, with 17 units of Trastuzumab returned by the UMO to the MACS Pharmacy, which represent 88,406.00 soles. The percentage of savings expressed in soles is 22.37%. On the other hand, it was found that the trend of savings by the UMO, is slightly negative with a coefficient of determination of Pearson (R2) of 0.1056. It is concluded that, during the study period, the use of trastuzumab was optimized; being the UMO service, one of the areas where great economic savings are generated